Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

著者: Timo Vesikari, Joanne M. Langley, Nathan Segall, Brian J. Ward, Curtis Cooper, Guillaume Poliquin, Bruce R. Smith, Soren Gantt, Janet E. McElhaney, Marc Dionne, Pierre Van Damme, Isabel Leroux‐Roels, Geert Leroux‐Roels, Nathalie Machluf, Johanna N. Spaans, Bebi Yassin-Rajkumar, David E. Anderson, Vlad Popovic, Francisco Díaz‐Mitoma, Timo Vesikari, Joanne M. Langley, Soren Gantt, Marc Dionne, Janet E. McElhaney, Bruce Rankin, Carl Griffin, Mark Turner, Judith L. Kirstein, Barbara Rizzardi, Hayes Williams, Anitta Ahonen, Olli Henriksson, Benita Ukkonen, Marita Paassilta, Nathan Segall, Brian J. Ward, Curtis Cooper, Guillaume Poliquin, Bruce R. Smith, Pierre Van Damme, Isabel Leroux‐Roels, Geert Leroux‐Roels, Nathalie Machluf, Johanna N. Spaans, Bebi Yassin-Rajkumar, David E. Anderson, Vlad Popovic, Francisco Díaz‐Mitoma - The Lancet 2021 被引用: 72